Home > Publications database > Statins and the risk of gynecological cancer: a Norwegian population-based cohort study. > print

001     303217
005     20250730114249.0
024 7 _ |a 10.1093/ije/dyaf133
|2 doi
024 7 _ |a pmid:40714826
|2 pmid
024 7 _ |a pmc:PMC12296387
|2 pmc
024 7 _ |a 0300-5771
|2 ISSN
024 7 _ |a 1464-3685
|2 ISSN
037 _ _ |a DKFZ-2025-01568
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Löfling, Leif Lukas
|b 0
245 _ _ |a Statins and the risk of gynecological cancer: a Norwegian population-based cohort study.
260 _ _ |a Oxford
|c 2025
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1753794862_3434
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:C180# / Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
520 _ _ |a Endometrial, ovarian, and cervical cancers are the most common gynecological cancers, with 1.4 million diagnoses worldwide in 2022. Statins are widely used for cardiovascular conditions and have been studied for their association with gynecological cancer risk, but results to date have been inconclusive.We conducted a population-based cohort study including data from the Norwegian Prescription Database and the Cancer Registry of Norway, and followed women aged ≥50 years from 2004 to 2018. We examined the association between statin use overall and by type (lipophilic, hydrophilic), and the risk of endometrial, ovarian, and cervical cancers overall and by age groups and histologic subgroup using Cox proportional hazard models.The cohort study included 1 083 629 women. During a median follow-up of 11.6 years, 334 582 (31%) used statins at least once. There were 7709 cases of endometrial, 4415 cases of ovarian, and 1603 cases of cervical cancers. Statin use was associated with reduced risk of endometrial cancer [current use hazard ratio (HR) = 0.90, 95% confidence interval (CI): 0.85-0.96; past use HR = 0.79, 95% CI: 0.71-0.88]; associations were observed only for the lipophilic statins, and with similar associations by age groups and for type I and II endometrial cancer. No consistent associations were found for ovarian or cervical cancers. We found no trends for cumulative defined daily doses of current use or time since cessation for any cancer type.Statin use was associated with a reduced risk of endometrial cancer but not with the risk of ovarian cancer or cervical cancer.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a cohort
|2 Other
650 _ 7 |a gynecological cancers
|2 Other
650 _ 7 |a population-based
|2 Other
650 _ 7 |a risk
|2 Other
650 _ 7 |a statins
|2 Other
650 _ 7 |a Hydroxymethylglutaryl-CoA Reductase Inhibitors
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Norway: epidemiology
|2 MeSH
650 _ 2 |a Hydroxymethylglutaryl-CoA Reductase Inhibitors: therapeutic use
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Uterine Cervical Neoplasms: epidemiology
|2 MeSH
650 _ 2 |a Ovarian Neoplasms: epidemiology
|2 MeSH
650 _ 2 |a Ovarian Neoplasms: prevention & control
|2 MeSH
650 _ 2 |a Endometrial Neoplasms: epidemiology
|2 MeSH
650 _ 2 |a Endometrial Neoplasms: prevention & control
|2 MeSH
650 _ 2 |a Proportional Hazards Models
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
650 _ 2 |a Registries
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
650 _ 2 |a Genital Neoplasms, Female: epidemiology
|2 MeSH
700 1 _ |a Støer, Nathalie C
|b 1
700 1 _ |a Botteri, Edoardo
|b 2
700 1 _ |a Turzanski-Fortner, Renée
|0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
|b 3
|e Last author
|u dkfz
773 _ _ |a 10.1093/ije/dyaf133
|g Vol. 54, no. 4, p. dyaf133
|0 PERI:(DE-600)1494592-7
|n 4
|p dyaf133
|t International journal of epidemiology
|v 54
|y 2025
|x 0300-5771
909 C O |o oai:inrepo02.dkfz.de:303217
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-20
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J EPIDEMIOL : 2022
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-20
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J EPIDEMIOL : 2022
|d 2024-12-20
920 2 _ |0 I:(DE-He78)C180-20160331
|k C180
|l Krebsepidemiologie
|x 0
920 1 _ |0 I:(DE-He78)C180-20160331
|k C180
|l Krebsepidemiologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C180-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21